All In MedTech

FDA Clearance Tracker · P160037-S005

BD Onclarity HPV Assay/BD COR System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 24, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P160037-S005
Device name
BD Onclarity HPV Assay/BD COR System
Applicant location
Sparks, MD
Received
Jan 14, 2020
Decided
Aug 24, 2021
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160037

Device type

Device class
Class III

Every decision under product code MAQ

FDA's approval statement

As written in FDA's record.

Approval for use of the BD Onclarity HPV Assay on the BD COR (PX/GX) instrument system.

Source documents

Other decisions for Becton, Dickinson and Company

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.